Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
AstraZeneca announced that the Phase III TULIP-SC trial of SAPHNELO (anifrolumab) for treatment of people with systemic lupus ...
The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
Wall Street analysts expect the subcutaneous version of Keytruda, which just launched this week, to help soften the blow when the original loses patent protection later this decade.
The FDA has approved Keytruda Qlex, a faster, under-the-skin cancer treatment offering convenience and flexibility. Here's what we know.
In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and ...
In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...
Pharmaceutical Technology on MSN
Halozyme eyes microparticles in $900m Elektrofi acquisition
Halozyme will purchase fellow subcutaneous drug delivery specialist Elektrofi for $750m upfront, along with with three ...
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback